Skip to content

SEARCH

Investing
Tech
Consumer
Financial
Politics
- Trump
- US Budget
Health
Basic Materials
- Agriculture
- Metals & Mining
  - Cobalt
  - Zinc
  - Gold
  - Silver
  - Lithium
  - Uranium
  - Copper
Energy
- Oil & Gas
- Alternative Energy
  - Biofuels
  - Hydro
  - Solar
Industrials

Search

SEARCH FOR AN ARTICLE

Search

Investing
Tech
Consumer
Financial
Politics
- Trump
- US Budget
Health
Basic Materials
- Agriculture
- Metals & Mining
  - Cobalt
  - Zinc
  - Gold
  - Silver
  - Lithium
  - Uranium
  - Copper
Energy
- Oil & Gas
- Alternative Energy
  - Biofuels
  - Hydro
  - Solar
Industrials

HomeADMS

ADMS

Adamas Pharmaceuticals’ Stock Skyrockets After its Drug Gocovri Gain FDA Approval

Adamas Pharmaceuticals’ Stock Skyrockets After its Drug Gocovri Gain FDA Approval

August 25, 2017

LATEST NEWS

Investing News Wall Street’s Best Week of 2024: Stock Market Weekly Gains
Investing News Rivian Stock: Buy Now or Take a Wait-and-See Approach?
Investing News Visa Stock Analysis: Is V a Strong Buy for 2025?
Investing News Intel Stock Recovery: Challenges and Future Outlook
Investing News Microsoft Stock Analysis: Buy, Sell, or Hold?

All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

Advertisers
Privacy Policy
Terms of Use
DMCA Policy
Disclaimer
Contact Us

SUBSCRIBE

To get email updates from StreetSignals.

I want e-mail alerts, updates, and offers and agree to the StreetSignals privacy policy.

Market Jar Media Inc. © 2024